This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delaney, W. E.
Right arrow Articles by Locarnini, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delaney, W. E., IV
Right arrow Articles by Locarnini, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 3057-3060, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3057-3060.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro

William E. Delaney, IV,1,{dagger} Ros Edwards,1 Danni Colledge,1 Tim Shaw,1 Phil Furman,2 George Painter,2 and Stephen Locarnini1*

Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia ,1 Triangle Pharmaceuticals, Durham, North Carolina 277072

Received 23 July 2001/ Returned for modification 17 December 2001/ Accepted 5 June 2002

The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type HBV with 50% inhibitory concentrations of 21.2 ± 9.5 and 2.40 ± 0.92 µM, respectively, compared to 0.064 ± 0.020 µM lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.

* Corresponding author. Mailing address: Victorian Infectious Diseases Reference Laboratory, Locked Bag 815, Carlton South, Victoria 3053, Australia. Phone: (61 3) 9342-2614. Fax: (61 3) 9432-2666. E-mail: stephenlocarnini{at}compuserve.com.

{dagger} Present address: Gilead Sciences, Foster City, CA 94402.

Antimicrobial Agents and Chemotherapy, September 2002, p. 3057-3060, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3057-3060.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dougherty, A. M., Guo, H., Westby, G., Liu, Y., Simsek, E., Guo, J.-T., Mehta, A., Norton, P., Gu, B., Block, T., Cuconati, A. (2007). A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen Secretion. Antimicrob. Agents Chemother. 51: 4427-4437 [Abstract] [Full Text]  
  • Kamiya, N. (2003). The mechanisms of action of antivirals against hepatitis B virus infection. J Antimicrob Chemother 51: 1085-1089 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»